Catalysts · VTRS · CIK 1792044 · page 2 of 2

VTRS catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on VTRS PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
August 14, 2019Pretomanid (pretomanid)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
August 6, 2019Epzicom (abacavir sulfate; lamivudine)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
June 6, 2019Acetaminophen (acetaminophen)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
November 9, 2018Yupelri (revefenacin)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
July 10, 2018Vancomycin Hydrochloride (vancomycin)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
June 4, 2018Fulphila (pegfilgrastim-jmdb)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
May 17, 2018nda210605VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
March 22, 2018Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
February 28, 2018Cimduo (lamivudine; tenofovir disoproxil fumarate)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
February 5, 2018Symfi Lo (efavirenz; lamivudine; tenofovir disoproxil fumarate)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
December 6, 2017Acetaminophen (acetaminophen)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
December 1, 2017Ogivri (trastuzumab-dkst)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
February 1, 2017Acetaminophen (acetaminophen)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
March 10, 2016Acetaminophen (acetaminophen)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
February 27, 2015Acetaminophen (acetaminophen)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
Every catalyst is quoted from VTRS’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.